PD98059

Catalog No.S1177

PD98059 Chemical Structure

Molecular Weight(MW): 267.28

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 470 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

10 Customer Reviews

  • a-c, Inhibitors of BRAFV600E (PLX4032) and MEK1/2 (PD98059 or AZD6244) increase PGC1α and ID2 expression (a, b) and repress integrin expression and signalling (b, c). Cells were treated with indicated concentration of inhibitors for 6 h (a, b) or 24 h (c). d, e, PLX4032 increases the interaction between ID2 and TCF4 (d) and decreases the occupancy of TCF4 at the promoters of integrin genes (e). f–g, PGC1α and ID2 are partially required for PLX4032-mediated inhibition of invasion and metastasis. For in vitro assays (f), A375 cells were incubated with 1 μM PLX4032 for 10 h. Images represent one picture captured per membrane with the scale bar representing 200 μm. Values in a, b, e and f represent mean±s.d. of independent biological triplicates; *P<0.05 and **P<0.01 by Student's t-test  in a, b, e, f.

    Nature, 2016, 537(7620):422-427.. PD98059 purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.

    effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) on SRP72 protein expression was evaluated on Jurkat cells stimulated with rhIL-1. The cells were harvested at 0,120, and 240 min, and the protein expression was verified by WB using antibodies against human SRP72, human SRP54 (nonphosphorylated SRP protein), and humanGAPDHas constitutive protein.Adecreased SRP72 expression at 10 μM and 240 min was found.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

  • C, effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) was evaluated in SRP72-immunoprecipitated cell lysates. WB using anti-phosphoserine antibody showed a decreased SRP72 band when used as the inhibitor at concentrations of 1 μM at 240 min, 5 μM at 120 min, and 10 μM at 120 and 240 min (lanes 3, 5, 8, and 9). D, results were analyzed and RUA illustrated, finding significant results at 1 μM at 240 versus 0, 5 μM at 120 versus 0, and 10 μM at 120 versus 0 min.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

    We used real time RT-PCR to investigate the effects of PD98059 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

  •  

    Activation of a TLR2eERK1/2 pathway in MDDC. (C) MDDC were either untreated or treated with C. pneumoniae alone or in the presence of the ERK1/2 inhibitor PD98059 for 48 h. IL-12p70 and IL-10 release in culture media was assessed by ELISA. (D) MDDC were treated as in panel C for 48 h and then cocultured with purified allogeneic CD3t T cells. On day 12, supernatants were collected, and secreted cytokines were measured by ELISA.

    Microbes Infect 2013 15, 105-14. PD98059 purchased from Selleck.

    HepG2 cells, “Pnt-2” primary HCC cells or THLE-2 normal liver cells were pretreated with PD-98059 (1 mM) or MEK-162 (“MEK”, 1 mM) for 1 h prior toWAY-600 (“WAY”, 100 nM) treatment, after applied period, cell viability and apoptosis were tested by MTT assay (F and H).

    Biochem Biophys Res Commun, 2016, 474(2):330-7.. PD98059 purchased from Selleck.

  • Collagen I and α-SMA are conducive for S. aureus adhesion to and invasion into BMFBs. BMFBs were treated with PD98059 2 h before the addition of 5 ng/ml TGF-β1; 24 h later, the adhesion (A) and invasion (B) assays were performed as previously described. The results are expressed as the mean cfu/ml ± SD from experiments performed in triplicate (*P < 0.05, **P < 0.01).

    Microb Pathog, 2017.. PD98059 purchased from Selleck.

    After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of  PD98059 for 3h,followed by 20-minute  stimolation of 100ng/ml EGF.

     

    2010 Dr. Zhang of Tianjin Medical University. PD98059 purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.
Features Does not inhibit c-Raf phosphorylated MEK1.
Targets
MEK1 [1]
(Cell-free assay)
2 μM
In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. [1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. [2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. [3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H1355 NFzm[HFHfW6ldHnvckBCe3OjeR?= MX[yOUDPxE1? NUH0fVdIOSCq M17MdoJtfW62czD0bIUhSlujXWCtbY5lfWOnZDDpcoNz\WG|ZTDpckBxcG:|cHjvMWNpczFiYX7kJJBpd3OyaH:tSXJMKGW6cILld5Nqd25? M4W3VFI2PzZ7MUix
MCF-7  MmjrSpVv[3Srb36gRZN{[Xl? MnnBNVAh|ryP M4TCVlEhcA>? MVPpcohq[mm2czDJUE0yQC2nbnjhcoNm\CClZXzsJI1q\3KjdHnvci=> MX:yOVczPzBzMR?=
HepG2  NUXRZWdSTnWwY4Tpc44hSXO|YYm= NEHRU40yOCEQvF2= NXnpTpY2PSCq M{PhO4Jtd2OtczDwbI9{eGixconsZZRm\CCPQWDLd{BqdmS3Y3XkJIJ6KGW6b3flco92eyCWR1[t{tIy NF7VXnozPTV4MES4PC=>
HepG2  NFnLPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWwO|VvOjBizszN M3jmR|I1KGh? MYTzeZBxemW|c3XzJHRITi4QskGtbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36gZY5lKGmwdnHzbY9v M2HYfVI2PTZyNEi4
MDA-MB-231 NIroNFBHfW6ldHnvckBCe3OjeR?= MXOyOUDPxE1? M1rad|IuOyCq MWjk[YNz\WG|ZYOgdE1GWktzL{KgZY5lKFNzMEDBOEBmgHC{ZYPzbY9v Mn;lNlU2PTV6N{W=
SW480 MlXaSpVv[3Srb36gRZN{[Xl? MVGyNOKh|ryP MmTyNeKhcA>? MlnVdoVlfWOnczD0bIUh\XiycnXzd4lwdiCxZjDBWGY{KHC{b4TlbY4> NHnV[5gzPTR2N{ixOi=>
HCT-15 Mn33SpVv[3Srb36gRZN{[Xl? M{fMb|EhcA>? NYjYOYNS[XS2ZX71ZZRmeyCSR1WyMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGVzc8Li MkHFNlU1OzF2MkW=
HCT-15 NVfNb45HSXCxcITvd4l{KEG|c3H5 MoHsNUBp MkWzZYJwdGm|aHXzJJRp\SCycn;0[YN1cX[nIHXm[oVkfHNib3[gVGdGOsLiYXfhbY5{fCCldYLjeY1qdi2rbnT1Z4VlKGGyb4D0c5Nqew>? NYO3Z3JrOjV2M{G0NlU>
786-O M3HIO2Fxd3C2b4Ppd{BCe3OjeR?= MnjYOVDDqM7:TR?= NVHweXdDOjRiaB?= MlHRdI91\W62aXH0[ZPDqHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeJMhd2ZiTlO= MoS4NlQ2ODh2N{[=
A498 NFizWGxCeG:ydH;zbZMhSXO|YYm= NUnlUVNVPTEEoN88US=> NFHpNWQzPCCq NW\XS|RVeG:2ZX70bYF1\XQEoITo[UBxem9vYYDvdJRwfGmlIHXm[oVkfHNib3[gUmM> MX[yOFUxQDR5Nh?=
NHBE NX65NJNZTnWwY4Tpc44hSXO|YYm= MV[yM|IxKM7:TR?= MoO4NkBp NFnTUmhifHSnboXheIV{KEmOLUOzJJN1cW23bHH0[YQhS1iFTEivTWwuQCC|ZXPy[ZRqd25? MmG0NlQ1Pzl3Mk[=
A375 NVrxd5lwS2WubDDJcpZie2mxbjDBd5NigQ>? NIP0bJQyOOLCk{KwJOK2VQ>? M4CzNVI1KGh? NHnnU2hz\WS3Y3XzJI1mdGGwb33hJINmdGxiaX72ZZNqd25? NG\lVW0zPDR4NkCzOi=>
HBMEC NIGxcWZHfW6ldHnvckBCe3OjeR?= MWOxNEDPxE1? M3W0TlEhcA>? M{TYe4Jtd2OtczDWSWdHNWmwZIXj[YQhTXCqQUKg[ZhxemW|c3nvci=> NG\JTnUzPDR3OEm4Ni=>
HPAEpiCs  NITsb2ZHfW6ldHnvckBCe3OjeR?= NHXIfZc{OCEQvF2= M4D0SlEhcA>? MX3pcohq[mm2czDUUmYu|rFic4TpcZVt[XSnZDDwOFIweDR2IF3BVGsheGixc4Doc5J6dGG2aX;u MXeyOFQ1OTh5MB?=
BeWo NGPyVXJHfW6ldHnvckBCe3OjeR?= MWWxNOKh|ryP NWTvV45zOiCq NWTNXFhCcW6qaXLpeJMhTVKNMT:y NFvGXIYzPDR|M{i0Oi=>
PC3  M33aZWFxd3C2b4Ppd{BCe3OjeR?= MYG1NEDPxE1? MXywMlUhcA>? NH21eVlqdmirYnn0d{BOUFlvNES5MYlv\HWlZXSgZZBweHSxc3nzxsA> M{TWOlI1PDJ2OEi5
HGC-27 MWrBdI9xfG:|aYOgRZN{[Xl? NIXJZVcyKML3TR?= NV7HN5h2OSCq M{HvN5N2eHC{ZYPz[ZMhWkGGMECxJJBtfXNiTVutNlIxPi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? MYGyOFQyPjN2OR?=
MCF-7 NHraOG9HfW6ldHnvckBCe3OjeR?= M1nRe|ExyqEQvF2= MnWwNVAwOzBibXnu MYTy[YR2[2W|IITo[UBWXFBvZHXw[Y5l\W62IFXST{BxcG:|cHjvdplt[XSrb36= M{\pS|I1OzlyOEG5
HUVECs MYDGeY5kfGmxbjDBd5NigQ>? NGjkXGsyOMLizszN NULlWJd[OSCq NEXIbI5qdmirYnn0d{B1cGViSFTMJJJm\HWlZXSgR29ZNTJiZYjwdoV{e2mxbjDhcoQhWEeLLUKgdoVt\WG|ZR?= NXLHRphuOjR|OEWxNFk>
HeLa MkDaSpVv[3Srb36gRZN{[Xl? MVO1NEDPxE1? MXqwMlUhcA>? MVXicI9kc3NiVGLYMVEhdnWlbHXhdkBucWe{YYTpc44h[W6mIGTYUmlRKGSxd36tdoVofWyjdHnvci=> M4HTb|I1Ozd4OEK3
HL-60  Mmq3SpVv[3Srb36gRZN{[Xl? M2i0SlExNzJyIN88US=> MnfnNUBp M2myWolvcGmkaYTzJJRp\cLiTj6gZ4hqdmWwc3nz[Zh1emGldNMgbY5lfWOnZDDkbYZn\XKnboTpZZRqd25iaX70c{BoemGwdXzvZ5l1\XN? NEG2R4UzPDN3N{CyNC=>
HL-60 NEOwZo5HfW6ldHnvckBCe3OjeR?= M{PFVFIhyrWP NIO1O4wyPiCq NXLneoNrTE2VTx?= Ml3GbY5pcWKrdIOgeIhmKGG|c3;jbYF1cW:wIH;mJJBUPjJzIGLh[k0yKGGwZDDOSmFV[zNuIHHu[EB1cGViUlGtbY5lfWOnZDDwbI9{eGixconsZZRqd25ib3[gcpVkdGWjcjDOSmFV[zN? MVSyOFM{ODB4OB?=
HEK 293 NF7NOVhHfW6ldHnvckBCe3OjeR?= NEDQflUyOCEQvF2= Mln5OUBp NHPTeopFVVOR M2D0b4lvcGmkaYTzJHdvfC2rbnT1Z4VlKM7{LXPheIVvcW5xVFPGOEBi[3Srdnn0fUBidmRiboXjcIVieiEQsj3jZZRmdmmwIHHjZ5VufWyjdHnvci=> M3;j[lI1OzJ2M{[2
HEK 293 NWHTWlcxTnWwY4Tpc44hSXO|YYm= NULOcmhsOTBizszN NGT3XHM2KGh? NWXTfoo5TE2VTx?= M2LxVZN2eHC{ZYPz[ZMhfGinIFPSWEBi[3Srdnn0fS=> NHXHWJIzPDN{NEO2Oi=>
SW480 M2nGZ2Z2dmO2aX;uJGF{e2G7 NX7heoY3OTBizszN NVPPTmd6OjBiaB?= NHrtRm1FVVOR NHfLe4d{fXCycnXzd4V{KHSqZTDDVnQh[WO2aY\peJk> NVPWVndFOjR|MkSzOlY>
HCSMCs M{LaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDs[Ik6OTBizszN Mn3rNlQhcA>? MnPyZoxw[2u|IF\BRnA1NWmwZIXj[YQhUEODU13DJJBzd2yrZnXyZZRqd25? NXHWZndlOjR|MUKzPFE>
PANC-1 NF3kZ3RHfW6ldHnvckBCe3OjeR?= MWCyNEDPxE1? NYi3V2dQPDhiaB?= M{DQZYlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJO6VPkRiaX6gdoV{eG:wc3WgeI8hfGinIGDQRXLPvMLiYXfvcol{fMLi NUfpWJJYOjR{OUSxN|M>
A549 MYfGeY5kfGmxbjDBd5NigQ>? MXezNEDPxE1? MmGyNE42KGh? MnLUSG1UVw>? M2PVUYlvcGmkaYTzJJRp\SC2aILvcYJqdi2rbnT1Z4VlKEmOLUivR3hEVDhvTIXjJIFkfGm4aYT5 MlHONlQzPzd4OU[=
A549 NITzc4RHfW6ldHnvckBCe3OjeR?= M1XzdlMxKM7:TR?= MlrNNE42KGh? NITzd2RFVVOR NWXrZopGcW6qaXLpeJMhfGi{b33ibY4ucW6mdXPl[EBEN0WEUN8yJHRpejJ|NdMgdIhwe3Cqb4L5cIF1cW:w MkfjNlQzPzd4OU[=
MC-3 Ml7QRZBweHSxc3nzJGF{e2G7 Mn\qNVAh|ryP M{HrRVI1KGh? NEHrTlFxd3SnboTpZZRm\CCPRWPDMYlv\HWlZXSgZZBweHSxc3nzJIlvKCClZXzsdy=> MUOyOFI4ODV{Mx?=
Raji  MnLBSpVv[3Srb36gRZN{[Xl? Mn;FNVAh|ryP M1zRNFEhcA>? MUjicI9kc3NiaIPCRWZHKGmwZIXj[YQhTXKtMT:yJJBpd3OyaH;yfYxifGmxbh?= Mn7SNlQzPjl4M{C=
Raji  NHHwdVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MluzNVAh|ryP NGXOWHAyKGh? NYTSd4hxcW6qaXLpeJMhfGinIHLhd4FtKG:{IHjzRmFHTi2|dHnteYxifGWmIHPlcIwheHKxbHnm[ZJifGmxbjDhcoQhfmmjYnnsbZR6 NH3qXm8zPDJ4OU[zNC=>
HT29 NInFb2xHfW6ldHnvckBCe3OjeR?= MoTBNVAh|ryP MnTXNkBp NIfhNodqdmirYnn0d{Bw\iCMQVuyMEBGWktzL{KgZY5lKFOWQWSzJJBpd3OyaH;yfYxifGmxbh?= NYT3WHlPOjR{NkWyPVM>
HepG2 NX[0NGxISXCxcITvd4l{KEG|c3H5 M2X0flIxKM7:TR?= NELCblQzPCCq MV7pcohq[mm2czDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGGwZDDlcohidmOnczDWRlEucW6mdXPl[EBieG:ydH;zbZM> Mn3PNlQzPDd7MEm=
HepG2 M2nXcmZ2dmO2aX;uJGF{e2G7 M372clIxKM7:TR?= NWHZeFVkOiCq NX\mN415\W6qYX7j[ZMhXkJzLXnu[JVk\WRiRl;YU|NiKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fS=> NUPmTnNuOjR{NEe5NFk>
TE4 Mof4SpVv[3Srb36gRZN{[Xl? M3LEVVIxNzVyL{GwNEDPxE1? MmPqOFghcA>? M4DueWROW09? NWf4OZl3cW6qaXLpeJMheC2HcnugZY5lKHexcoTtZY5vcW5iZH;3cpJm\3WuYYTl[EBxNUGtdDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1u0U|I1OjR2MEKz
TE1 NVjYO3NVTnWwY4Tpc44hSXO|YYm= MYqyNE82OC9zMECg{txO NX24U5lEPDhiaB?= NGDsS3VFVVOR MWLpcohq[mm2czDwMWVzcyCjbnSge49zfG2jbn7pckBld3ewcnXneYxifGWmIICtRYt1KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWmyOFI1PDB{Mx?=
KYSE30 M2POWGZ2dmO2aX;uJGF{e2G7 M3roWFIxNzVyL{GwNEDPxE1? M3v6cVQ5KGh? MkLrSG1UVw>? M3nqcYlvcGmkaYTzJJAuTXKtIHHu[EB4d3K2bXHucolvKGSxd37y[Yd2dGG2ZXSgdE1Cc3RiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3vLXFI1OjR2MEKz
TE1 NGqzdJVHfW6ldHnvckBCe3OjeR?= M4P2NFUxKM7:TR?= NVjVW2x4PDhiaB?= Ml\SSG1UVw>? NX;ONlQ4fXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm= MWiyOFI1PDB{Mx?=
TE3 M3K5NGZ2dmO2aX;uJGF{e2G7 NXTINHAzPTBizszN MWK0PEBp NXXvclcxTE2VTx?= NXnQR5NKfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm= NW[3fJhoOjR{NESwNlM>
TE4 Mlf2SpVv[3Srb36gRZN{[Xl? MXS1NEDPxE1? NIXvOpM1QCCq Ml3mSG1UVw>? NHHFeld2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKTFGgZ4xie3NiSR?= M1HRPFI1OjR2MEKz
TE5 NX2yOWM1TnWwY4Tpc44hSXO|YYm= NUHxZlZLPTBizszN NIjnfHc1QCCq M3\HTmROW09? MYj1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>? NEflN28zPDJ2NECyNy=>
KYSE30 MoiySpVv[3Srb36gRZN{[Xl? Mk\hOVAh|ryP NXSwRXBTPDhiaB?= NWPPUoQ3TE2VTx?= NUDHNmlbfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm= MkG1NlQzPDRyMkO=
MKN7 NUHHVG1HTnWwY4Tpc44hSXO|YYm= MoLIOVAh|ryP NYPmNXZFPDhiaB?= M2fwTmROW09? MorabY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= MV6yOFI1PDB{Mx?=
OE19 M1LRcmZ2dmO2aX;uJGF{e2G7 NFn5dGI2OCEQvF2= MUK0PEBp M13aUGROW09? NUThTm42cW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> M3z5dlI1OjR2MEKz
KATOIII  MVTGeY5kfGmxbjDBd5NigQ>? MlzJOVAh|ryP M4rXSlQ5KGh? NHW5OWVFVVOR NUS3fVRocW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> MUSyOFI1PDB{Mx?=
NCI-N87  NWn6b|NoTnWwY4Tpc44hSXO|YYm= NEe1XI82OCEQvF2= M17OUVQ5KGh? NU\4[oVUTE2VTx?= MlX1bY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= MWOyOFI1PDB{Mx?=
NUGC3 M17JOmZ2dmO2aX;uJGF{e2G7 MXy1NEDPxE1? NUfwbJg2PDhiaB?= NXTtN243TE2VTx?= MoHibY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= MlzHNlQzPDRyMkO=
NUGC2 NUL6b5o6TnWwY4Tpc44hSXO|YYm= MlfWOVAh|ryP NFHqc4w1QCCq M2XWNGROW09? NUf6d2hLcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> NYLKc3dFOjR{NESwNlM>
SGC-7901  M3vtZ2Fxd3C2b4Ppd{BCe3OjeR?= NV3QPJRkOjBizszN NHe1Z|IzPCCq MkLPbY5pcWKrdIOgR3AudWWmaXH0[YQh[XCxcITvd4l{ MYiyOFI1OTN3MR?=
MG-63 NGPmVmhHfW6ldHnvckBCe3OjeR?= NVjSXW44OjBizszN Mn\ONE42KGh? MoTaZoxw[2u|IITo[UBEUC2rbnT1Z4VlKHCqb4PwbI9zgWyjdHXkJGVNUzFicILveIVqdiCneIDy[ZN{cW:w MlLVNlQzOzl4NEC=
ARPE-19 M3SwT2Z2dmO2aX;uJGF{e2G7 NXvFOGt5OjBizszN NW\ofGRrOC53IHi= NULEVodVcW6qaXLpeJMhSXCnbHnuMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGVzcyCjbnSgRYt1 MUSyOFIzPzlzOB?=
CRL-2302 MWXGeY5kfGmxbjDBd5NigQ>? MnfHNlAh|ryP M1P6O|AvPSCq M1n1UolvcGmkaYTzJGFx\Wyrbj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDFdosh[W6mIFHreC=> MXqyOFIzPzlzOB?=
MCF-7 MkXSSpVv[3Srb36gRZN{[Xl? MVuyNEDPxE1? M2Hkd|EhcA>? MlzzZYJwdGm|aHXzJIV5eHKnc4Ppc44hd2ZicHjvd5Bpd3K7bHH0[YQhTVKNIHPvMZRz\WG2bXXueEB4cXSqIHPvcop2\2G2ZR?= NECycnQzPDJzNkK4PS=>
MCF-7 NFzZfpVCeG:ydH;zbZMhSXO|YYm= NF3GWo4zOCEQvF2= NX\JSo81OSCq MXHpcoNz\WG|ZYOgZ4F{eGG|ZT25JIVvgnmvZTDhZ5Rqfmm2eR?= MUGyOFIyPjJ6OR?=
DLD-1  MoLvSpVv[3Srb36gRZN{[Xl? NFXLVZUzOMLizszN MVe0PEBp M4XrTJJm\HWlZYOgeIhmKEKQSWCzJIV5eHKnc4Ppc44heHKnLYTy[YF1\WRid3n0bEA2NWG8YT3kRy=> MUSyOFIyOTV6MR?=
HT-29 NULHNmRZTnWwY4Tpc44hSXO|YYm= M4LVfVIxyqEQvF2= NG\HSnM1QCCq MVvy[YR2[2W|IITo[UBDVkmSMzDlfJBz\XO|aX;uJJBz\S22cnXheIVlKHerdHigOU1igmFvZFO= MWmyOFIyOTV6MR?=
7402 M3TIT2Fxd3C2b4Ppd{BCe3OjeR?= MV:zNEDPxE1? MVK1JIQ> MkP1[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=> NIHpVFEzPDJzMUK1Ny=>
7721 NXP1UpB1SXCxcITvd4l{KEG|c3H5 M2jlPVMxKM7:TR?= M{GwV|Uh\A>? NUHzdJg5\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? NEnzeGozPDJzMUK1Ny=>
SGC7901  M1L6cmFxd3C2b4Ppd{BCe3OjeR?= NFLkOYo2OMLizszN NGD6OmszPC92OD:3NkBp NHrid4hFVVOR MVXpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEqDS{Kgd4hTVkF? MX[yOFE4QDJ2MB?=
SMMC7721 NInnWIhHfW6ldHnvckBCe3OjeR?= NXLCOGt{OjVxNUCg{txO NILTRm8zPCCq NGm4eXB{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKHBvQXv0JI9zKHBvRWLLNU8zyqB? M2TtVVI1OTZ6MEW2
MCF-7 M37kd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfLN4IyOCEQvF2= MnfzOFhp NU\mbZlbTE2VTx?= NX[4O2t3emW4ZYLz[ZMhSk6ILXnu[JVk\WRiY3XscEBkgWOuZTDhdpJme3R? M{fDR|I1OTZ|NEC0
Caco-2 NH62VXBHfW6ldHnvckBCe3OjeR?= M3G3Z|UxyqEQvF2= M1XZN|Q5cA>? MWjEUXNQ MkPs[Y5p[W6lZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBUS06QMVGsSnh[TDNuwrDMR3QtyqCOT2isxsBJUUZ|QT|CpHpIOTZuwrDQSGU3ScLiYX7kxsBNT0GOU{G2xsBo\W6nc9MgZ48ufHKnYYTl[EB4cXSqIFTlfC=> MWmyOFE3OTZ7NR?=
HAECs NVPmVJVOTnWwY4Tpc44hSXO|YYm= MWmxNEDPxE1? NFT0Rm8yKGh? MXtCpIF1fGWwdXH0[ZMhXE6ILd8xMZN1cW23bHH0[YQhUUODTT2xJIFv\CCYQ1HNMVEh\XiycnXzd4lwdg>? MXmyOFE{PDZ3Nx?=
Ca9-22 Ml:xSpVv[3Srb36gRZN{[Xl? MmfPN{DPxE1? NEizNlIyKGh? MmT6ZYJwdGm|aHXzJJRp\SCjYnnsbZR6KG:oIFjiVkB1dyCrbnT1Z4UhUUxvODDwdo9lfWO2aX;u Mn:2NlQyOjZ3M{K=
Ca9-22 MkP5SpVv[3Srb36gRZN{[Xl? MUWzJO69VQ>? MkTvNU8zKGh? Mn:5doVlfWOnczDIZnIucW6mdXPl[EBCXEZvMjDwbI9{eGixconsZZRqd25? MVuyOFEzPjV|Mh?=
AGS NXLvcHNwTnWwY4Tpc44hSXO|YYm= M1\TXlExKM7:TdMg NXXrT2lXOC53IHi= NVjDc4tucW6qaXLpeJMhfGinIIXwdoVofWyjdHnvckBw\iC2aHWgTWwuQCCpZX7l M1HCflI1OTB4MU[2
Caco-2  M3TveGFxd3C2b4Ppd{BCe3OjeR?= M1GzTlExyqEQvF2= MWCyOOKhcA>? Mme1[IVkemWjc3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgOU1HXQ>? NWTSXZB2OjRyOUW4OlM>
HCT-8 M{XRSGFxd3C2b4Ppd{BCe3OjeR?= M3;GflExyqEQvF2= NYLjTWpSOjUEoHi= M3fUWYRm[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JFUuTlV? NH\qSmQzPDB7NUi2Ny=>
A549 NEnaOYVHfW6ldHnvckBCe3OjeR?= MWW1NOKh|ryP NX;vUVh[OiCq MonhZoxw[2u|IFXST{BxcG:|cHjvdplt[XSrb36gcYVlcWG2ZXSgZpkhOSx{LV7R MnTLNlQxPjd5Mke=
HPMC MmXHSpVv[3Srb36gRZN{[Xl? M3HpZlExyqEQvF2= Mmj1OFghcA>? MlS3doV3\XK|ZYOgeIhmKGOqYX7n[ZMhcW5iY3XscEBud3KyaH;sc4d6KGmwZIXj[YQh[nliSFfQSHM> NIS2[WczPDB2MkizPC=>
HPMC NXvCem9ySXCxcITvd4l{KEG|c3H5 MUKxNOKh|ryP M2fwU|I1yqCq NWPaNnQ1emW4ZYLz[ZMh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW6mdXPl[EBjgSCKR2DEVy=> MnX6NlQxPDJ6M{i=
MGC803  Mn\4RZBweHSxc3nzJGF{e2G7 NYL6ZYtqOjEEoN88US=> MmnGNUBp MnnMbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhUU[QLd8xxsBidmRiNfMAtk1FTlWU NUXUfZdVOjRyMke3OVA>
SGC7901 MYHBdI9xfG:|aYOgRZN{[Xl? NXHzZpNIOjEEoN88US=> MlLoNUBp MnfkbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhUU[QLd8xxsBidmRiNfMAtk1FTlWU MYqyOFAzPzd3MB?=
COLO205 MkPERZBweHSxc3nzJGF{e2G7 MYWxNE8zOC92MDFOwG0> MnvxNlQhcA>? M{\IO4lv\HWlZYOgSG5CKGyjZHTldkBnd3KvYYTpc44> M1;3VVI1ODF7MUC4
G292  NIjxO5FCeG:ydH;zbZMhSXO|YYm= M4e5N|MxyqEQvF2= MYiyJIg> NYm2fVFoemW|dH;y[ZMh[2Gyc3HpZ4lvNWmwZIXj[YQh[2WubDDk[YF1cA>? MU[yOFAyOjl|MB?=
BxPC-3 MYLGeY5kfGmxbjDBd5NigQ>? NWnmN2tVOTBizszNxsA> NF3qNGU3KGh? MUXpcoNz\WG|ZTDtbXIuOTR|IHX4dJJme3Orb36= M1;1NVI{QTd|N{Gw
HPAF-II Mm\RSpVv[3Srb36gRZN{[Xl? MnL4NVAh|ryPwrC= Mn\JOkBp MXnpcoNz\WG|ZTDtbXIuOTR|IHX4dJJme3Orb36= NWP4NFNPOjN7N{O3NVA>
HL-60 NEfHVFBCeG:ydH;zbZMhSXO|YYm= NWruPXQ4PTEEoN88US=> NY\VSXhkOSCq MnnFdoV{[3WnczDCRVE1PSCvZXTpZZRm\CCjcH;weI9{cXN? MUOyN|k1QDd3MR?=
HepG2 MnvlSpVv[3Srb36gRZN{[Xl? NXjlbGdWPDBizszN M1q4bFYwOTJiaB?= NVfqSJl5cW6qaXLpeJMhfGinIHnuZ5Jm[XOnIH;mJJAuTVKNMTDhcoQheC2lLVr1ckBxem:2ZXnuJIV5eHKnc4Ppc44h[nliUFy= MX6yN|k1Ojh3MR?=
HUVECs MX;GeY5kfGmxbjDBd5NigQ>? MVyyOUDPxE1? NVLzSJV3OSCq M17kNIlv[3KnYYPlJG5HNc78QjDwOlUhdnWlbHXhdkB1emGwc3zvZ4F1cW:w MVeyN|kxOTByOB?=
LNCaP  MYTGeY5kfGmxbjDBd5NigQ>? NGrw[2QyOCEQvF5CpC=> MUCxJIg> MXjk[YNz\WG|ZYOgeIhmKEWJRjD1dJJm\3WuYYTl[EBxNVmELUG= MkPaNlM5Ozh|MUi=
HL60  MXvGeY5kfGmxbjDBd5NigQ>? M{foRlIxyqEQvF2= M3noNFczKGh? M4HxfWROW09? NWPNSWlicW6qaXLpeJMh\GG|YYTpcoljNWmwZIXj[YQhS0RzMXKg[ZhxemW|c3nvci=> MmLrNlM5OjV3OEW=
NB4  NFfEboRHfW6ldHnvckBCe3OjeR?= NFvrd5UyOCEQvF5CpC=> MlvQO|IhcA>? MUDEUXNQ MVTpcohq[mm2czDkZZNifGmwaXKtbY5lfWOnZDDDSFEy[iCneIDy[ZN{cW:w MX[yN|gzPTV6NR?=
EPOR/CR3 MXzGeY5kfGmxbjDBd5NigQ>? NHHFNWg2OMLizszN NFPPO5o{KGh? NX3IS5hWemWmdXPld{BGWE9iYX7kM49zKEmOLUOtbY5lfWOnZDD0bIUhfHm{b4PpcoUheGixc4Doc5J6dGG2aX;uxsA> MYKyN|gzODd|MR?=
HUASMCs NW\iW5RETnWwY4Tpc44hSXO|YYm= Mk\BNVAh|ryPwrC= MXGyOEBp NGDtO3llcW2rbnnzbIV{KEGwZzDJTU1k[XW|ZXSgV29EWzNibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wwrC= MWmyN|gyPjR4OB?=
HUASMCs MVTGeY5kfGmxbjDBd5NigQ>? NYW2ZYdmOTBizszNxsA> M{\iclI1KGh? MUXpcohq[mm2czDBcochUUlvaX7keYNm\CCHUluxM|IheGixc4Doc5J6dGG2aX;uJIxmfmWu MX:yN|gyPjR4OB?=
SGC7901 MkGxSpVv[3Srb36gRZN{[Xl? M4\PNFExKM7:TdMg NVLXe4w{OjRiaB?= NFfjc4lqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxcG:|cHjvdplt[XSnZDDFVmsyNzJ? NF:xWW0zOzd7MkW4PC=>
MKN45 M1HwSmZ2dmO2aX;uJGF{e2G7 MWexNEDPxE4EoB?= NUf6ZpYyOjRiaB?= M17XdIlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGWmIFXST|EwOg>? NEn5ZYQzOzd7MkW4PC=>
SGC7901 NUi2OXFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PPVVExKM7:TdMg NU\4dWwzOjRxNEivO|IhcA>? NFzHPIxqdmirYnn0d{Bk\WyuIHfyc5d1cCClbz30doVifGWmIIfpeIghTEGSVB?= M2n0UlI{Pzl{NUi4
MKN45 MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHaNVAh|ryPwrC= Mmf0NlQwPDhxN{KgbC=> MVHpcohq[mm2czDj[YxtKGe{b4f0bEBkdy22cnXheIVlKHerdHigSGFRXA>? NGDGfowzOzd7MkW4PC=>
SGC7901 M4rzc2Fxd3C2b4Ppd{BCe3OjeR?= MWSxNEDPxE4EoB?= NF;NWm8zPCCq NYjHenZkcW6lcnXhd4V{KHSqZTDERXBVNWmwZIXj[YQh[2WubDDhdI9xfG:|aYO= MYCyN|c6OjV6OB?=
MKN45 NGmzdVZCeG:ydH;zbZMhSXO|YYm= MXOxNEDPxE4EoB?= M{DOXlI1KGh? NXnVSIpLcW6lcnXhd4V{KHSqZTDERXBVNWmwZIXj[YQh[2WubDDhdI9xfG:|aYO= Mn\KNlM4QTJ3OEi=
BxPC-3 cells M13nWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP0OGkzOMLizszN MVuwMlUhcA>? MmjDbY5pcWKrdIOgWmVITi2DLYLl[5Vt[XSnZDDIWXZGSyCpcn;3eIgh[W6mIIT1ZoUh\m:{bXH0bY9vKGmwZIXj[YQh[nliUFHSMVIhSVB? NYPoT3FZOjN5NkSwOFY>
NB4  M1jNOmFxd3C2b4Ppd{BCe3OjeR?= MXOxNE8zOC94MDFOwG0> NY[4fIF6OS53IHi= MnO0SG1UVw>? MV;k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliY3:teJJm[XSnZDD3bZRpKFCjY3zpeIF5\Wx? MoHiNlM4OzV3NEG=
HepG2  MVnGeY5kfGmxbjDBd5NigQ>? NIrZcZIzOMLizszN M4DjXlI1KGh? MmPkbY5pcWKrdIOgeIhmKEiRLUGgdJJwfGWrbjDlfJBz\XO|aX;uJINwNXS{ZXH0[YQhf2m2aDDt[ZRnd3KvaX6= M3e1U|I{PzB5NkC5
HUVECs MnSwRZBweHSxc3nzJGF{e2G7 MYWyM|Qh|ryP NH;jSWIzPC92ODDo Mo\zbY5lfWOnczDj[YxtKGSnYYTo MWqyN|cxPzV{MB?=
KG-1  M4WzbGFxd3C2b4Ppd{BCe3OjeR?= NHq0eXIzOMLizszN MYexNkBp Mn;s[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDTNS=> NWKxfoxKOjN5ME[2PVE>
AML 1# NYrkNlZ1SXCxcITvd4l{KEG|c3H5 MljQNlDDqM7:TR?= M4\5NVEzKGh? NYj1N4JS\W6qYX7j[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBUOQ>? NVj1V2RbOjN5ME[2PVE>
A2780  NV3vWHhtTnWwY4Tpc44hSXO|YYm= NXm0b41lOjEEoN88US=> MVexJIg> NWf1[WFt[myxY3vzJGRVS0RvaX7keYNm\CCGUkWg[ZhxemW|c3nvci=> MUCyN|Y6Pjh4Mh?=

... Click to View More Cell Line Experimental Data

In vivo Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. [5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. [6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. [7]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro MEK-inhibitory activity:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl2/2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research:

[1]

+ Expand
  • Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 3 dyas, or 7-10 days
  • Method:

    For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male Sprague–Dawley rats with acute pancreatitis
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 10 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (52.37 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 267.28
Formula

C16H13NO3

CAS No. 167869-21-8
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to formulate this inhibitor for i.p. injection?

  • Answer:

    You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD98059 | PD98059 supplier | purchase PD98059 | PD98059 cost | PD98059 manufacturer | order PD98059 | PD98059 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID